Sugi Predict

Sugi Predict / Compounds / SCHEMBL22554949

SCHEMBL22554949

SCHEMBL22554949

COC1C(=O)N(Cc2ccccc2)C1(C)CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ CTSG P08311 1/20 0.34
▸ PRTN3 P24158 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ GRM5 P41594 3/20 0.33
▸ FAAH O00519 1/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ TOP2A P11388 1/20 0.33
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17685932 0.75 THRB (0.34) ELANEALDH1A1HSD11B1THRBLMNA
SCHEMBL22555271 0.75 ADRA2A (0.37) THRB
SCHEMBL17685971 0.72 ELANE (0.38) ELANEALDH1A1HSD11B1THRBCTSG
SCHEMBL4751071 0.70 ALDH1A1 (0.43) ELANEALDH1A1HSD11B1GAA
SCHEMBL4748906 0.70 ALDH1A1 (0.43) ELANEALDH1A1HSD11B1GAA
SCHEMBL19338992 0.69 ALDH1A1 (0.42) ELANEALDH1A1THRBCTSGPRTN3
SCHEMBL17426079 0.68 ALDH1A1 (0.41) ELANEALDH1A1THRBCTSGPRTN3
SCHEMBL19290851 0.67 ALDH1A1 (0.38) ELANEALDH1A1THRBCTSGPRTN3
SCHEMBL18306073 0.66 MEN1 (0.49) ELANEALDH1A1THRBCTSGPRTN3
SCHEMBL8066368 0.66 DRD4 (0.34) THRBTOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289830-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2025-09-18 — — US disclosed
US-12351591-B2 KRas inhibitors ELI LILLY AND COMPANY (US) 2025-07-08 — — US disclosed
EP-4499233-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2025-02-05 — — EP disclosed
CN-119095853-A KRAS inhibitors 伊莱利利公司 2024-12-06 — — CN disclosed
US-20240043451-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-02-08 — — US disclosed
WO-2023183585-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2023-09-28 — — WO disclosed
WO-2023183585-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2023-09-28 — — WO disclosed
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 — — US disclosed
EP-4087573-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2022-11-16 — — EP disclosed
US-20200331911-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2020-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS ELANE 1876/4885ALDH1A1 3370/4885HSD11B1 1557/4885
US-20240043451-A1 KRAS INHIBITORS KRAS, NRAS, HRAS ELANE 1896/4885ALDH1A1 1852/4885HSD11B1 2043/4885
US-20200331911-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS ELANE 1876/4885ALDH1A1 3370/4885HSD11B1 1557/4885
US-12351591-B2 KRas inhibitors KRAS, NRAS, HRAS ELANE 1896/4885ALDH1A1 1852/4885HSD11B1 2043/4885
US-20250289830-A1 KRAS INHIBITORS KRAS, NRAS, HRAS ELANE 1896/4885ALDH1A1 1852/4885HSD11B1 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.